

Press release, April 30, 2010

## New number of shares and votes in Biovitrum AB (publ)

The total number of shares in Biovitrum AB (publ) as per April 30, 2010 amounts to 212,414,439 shares, whereof 211,898,854 common shares and 515,585 class C shares<sup>1</sup>, corresponding to in total 211,950,412.50 votes. The increase in the number of shares and votes results from a conversion of previously issued convertibles into a total of 2,373,300 common shares to the vendors of Cambridge Biotechnology Limited.

*For further information, please contact:*

Göran Arvidson, CFO Biovitrum  
Phone: +46 70 633 30 42

Erik Kinnman, EVP Investor Relations Biovitrum  
Phone: +46 73 422 15 40  
[erik.kinnman@biovitrum.com](mailto:erik.kinnman@biovitrum.com)

### About Swedish Orphan Biovitrum

On January 14, 2010, Biovitrum AB (publ) completed the acquisition of Swedish Orphan International Holding AB and created Swedish Orphan Biovitrum – a leading company focused on treatment of rare diseases.

Swedish Orphan Biovitrum is a Swedish based specialty pharmaceutical company with an international market presence. The company is focused on providing and developing orphan and niche specialist pharmaceuticals to patients with high medical needs. The portfolio consists of about 60 marketed products and an emerging late stage clinical development pipe-line within rare diseases. Swedish Orphan Biovitrum has pro-forma revenues 2009e of about 2 BSEK and approximately 500 employees. The head office is located in Sweden and the share (STO: BVT) is listed on NASDAQ OMX Stockholm. For more information please visit [www.biovitrum.com](http://www.biovitrum.com).

*The above information has been made public in accordance with the Securities Market Act and/or the Financial Instruments Trading Act. The information was published at 11:45 a.m CET on April 30, 2010.*

---

<sup>1</sup> All class C shares are held by Biovitrum.